Spire Wealth Management Has $893,000 Stake in Novo Nordisk A/S (NYSE:NVO)

Spire Wealth Management lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 8.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,862 shares of the company’s stock after purchasing an additional 978 shares during the period. Spire Wealth Management’s holdings in Novo Nordisk A/S were worth $893,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Revolve Wealth Partners LLC lifted its stake in shares of Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after buying an additional 200 shares during the last quarter. IFP Advisors Inc boosted its position in Novo Nordisk A/S by 5.4% during the 4th quarter. IFP Advisors Inc now owns 11,558 shares of the company’s stock worth $994,000 after buying an additional 594 shares during the period. Proficio Capital Partners LLC bought a new position in Novo Nordisk A/S during the 4th quarter worth approximately $13,282,000. Sentinel Trust Co. LBA raised its holdings in Novo Nordisk A/S by 0.4% during the 4th quarter. Sentinel Trust Co. LBA now owns 44,366 shares of the company’s stock worth $3,816,000 after purchasing an additional 194 shares during the last quarter. Finally, Illumine Investment Management LLC bought a new position in Novo Nordisk A/S during the 4th quarter worth approximately $242,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Up 1.2%

Novo Nordisk A/S stock opened at $68.50 on Friday. The firm has a 50 day moving average of $69.11 and a 200 day moving average of $77.28. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $145.99. The firm has a market capitalization of $305.85 billion, a price-to-earnings ratio of 20.27, a P/E/G ratio of 1.21 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting analysts’ consensus estimates of $0.92. The company had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. As a group, research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. BNP Paribas assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They set an “underperform” rating on the stock. Hsbc Global Res upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, April 28th. Guggenheim cut Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 17th. Stifel Nicolaus cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Finally, Dbs Bank cut Novo Nordisk A/S to a “sell” rating in a research report on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.